At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 806 enrolled
Drug / intervention
bimatoprost 0.01% ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-year, Multicenter, Double-masked, Randomized, Parallel Study of the Safety of LUMIGAN® 0.1 mg/mL Compared With LUMIGAN® 0.3 mg/mL in Patients With Glaucoma or Ocular Hypertension
In Brief
A Phase 4 clinical trial evaluating bimatoprost 0.01% ophthalmic solution and bimatoprost 0.03% ophthalmic solution for Glaucoma and Ocular Hypertension. Completed, enrolled 806 participants across 50 sites in 10 countries.
Detailed Summary
This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesBelgium, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Spain, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMay 2011
Primary CompletionDec 2016
TodayJul 2026
First PostedFeb 18, 2011
Enrollment StartMay 31, 2011
Primary CompletionDec 6, 2016
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 15.4 years ago
Interventions
bimatoprost 0.01% ophthalmic solutiondrug
One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
bimatoprost 0.03% ophthalmic solutiondrug
One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.